Objective
State the stability objective, product, dosage form, strength, and intended filing or monitoring use.
4.8
on G2
Free Pharma & Biotech Template
ICH stability protocol for [product_name] batches
Use this template to iCH stability protocol for [product_name] batches.
| Field | Details |
|---|---|
| Category | Pharma & Biotech |
| Owner | [Team or owner] |
| Version | [Version number] |
| Effective Date | [Date] |
| Review Cycle | [Monthly / Quarterly / Annual / Event-based] |
| Status | [Draft / In Review / Approved] |
State the stability objective, product, dosage form, strength, and intended filing or monitoring use.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Identify batches, packaging configurations, batch size, manufacturing dates, and study type.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
List long-term, intermediate, accelerated, and special conditions with temperature and humidity ranges.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Define pull points, sample quantities, test panels, and retain requirements.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
List method numbers, validation status, laboratories, and sample handling expectations.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Define specifications for assay, impurities, dissolution, appearance, moisture, and microbiology where applicable.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Describe chamber monitoring, missed pulls, OOS/OOT handling, data review, and report approval. Use concise regulatory language and tables for conditions and time points.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Document review conclusions, approvals, unresolved items, and next review date.
| Role | Name | Date | Notes |
|---|---|---|---|
| Preparer | [Name] | [Date] | [Notes] |
| Reviewer | [Name] | [Date] | [Notes] |
| Approver | [Name] | [Date] | [Notes] |
Template Structure
Use this pharma & biotech template as a starting point, then customize each section to match your internal workflow, evidence, and signoff needs.
State the stability objective, product, dosage form, strength, and intended filing or monitoring use.
Identify batches, packaging configurations, batch size, manufacturing dates, and study type.
List long-term, intermediate, accelerated, and special conditions with temperature and humidity ranges.
Define pull points, sample quantities, test panels, and retain requirements.
List method numbers, validation status, laboratories, and sample handling expectations.
Define specifications for assay, impurities, dissolution, appearance, moisture, and microbiology where applicable.
Describe chamber monitoring, missed pulls, OOS/OOT handling, data review, and report approval. Use concise regulatory language and tables for conditions and time points.
Write an ICH-style Stability Protocol. Structure with these Markdown sections:
State the stability objective, product, dosage form, strength, and intended filing or monitoring use.
Identify batches, packaging configurations, batch size, manufacturing dates, and study type.
List long-term, intermediate, accelerated, and special conditions with temperature and humidity ranges.
Define pull points, sample quantities, test panels, and retain requirements.
List method numbers, validation status, laboratories, and sample handling expectations.
Define specifications for assay, impurities, dissolution, appearance, moisture, and microbiology where applicable.
Describe chamber monitoring, missed pulls, OOS/OOT handling, data review, and report approval.
Use concise regulatory language and tables for conditions and time points.
Evaluate stability of DBX-100 100 mg tablets in HDPE bottles for annual commitment batches.
Three production batches will be placed on long-term and accelerated stability.
| Condition | Temperature | Humidity |
|---|---|---|
| Long-term | 25 C | 60% RH |
| Accelerated | 40 C | 75% RH |
Pull samples at 0, 3, 6, 9, 12, 18, and 24 months.
Assay and impurities use validated method AM-DBX-011.
Assay must remain 90.0% to 110.0% of label claim.
OOT results require QA notification within one business day.
Record a walkthrough, training session, or process demonstration. Docsie AI turns it into structured documentation using this template as the starting framework.
Use the template manually, or let Docsie generate the first draft from source footage.
APQR report for [product_name] covering [review_period]
Controlled record for manufacturing [product] batch [batch_number]
Corrective and preventive action plan for [quality_issue]
Controlled assessment for proposed GMP change to [system_or_process]
Protocol for validating cleaning of [equipment_or_process_train]
GMP deviation investigation for [event] affecting [batch_or_process]
Template FAQ
Common questions about using and generating a stability Protocol.
Q: What is a stability Protocol?
A: A stability Protocol is a structured document for ich stability protocol for [product_name] batches.
Q: Can I download this stability Protocol as Word or PDF?
A: Yes. This page includes free downloads in DOCX, PDF, and Markdown formats so you can edit, share, or import the template into your documentation system.
Q: Can Docsie generate this from a video?
A: Yes. Upload a process walkthrough, training recording, or screen capture to Docsie, then use this template structure to generate a first draft automatically.